Mission Statement, Vision, & Core Values of ImmunityBio, Inc. (IBRX)

Are you intrigued by companies that aim to revolutionize healthcare? What if a company's core values could drive groundbreaking advancements in medicine? Consider ImmunityBio, Inc. (IBRX), a pioneering biotechnology company with a mission to revolutionize cancer treatment and improve patient outcomes through innovative immunotherapy solutions. But how do their mission, vision, and core values translate into real-world impact, especially when facing financial challenges with a net loss of $413.6 million for the year ended December 31, 2024?

With a vision to create a world where cancer is no longer a life-threatening disease, ImmunityBio is focused on developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. How do innovation, collaboration, integrity, and patient-centricity shape their operations and empower them to make a meaningful difference, despite financial headwinds? Read on to explore the driving forces behind ImmunityBio.

ImmunityBio, Inc. (IBRX) An Overview of

ImmunityBio, Inc., is a clinical-stage immunotherapy company focused on developing therapies and vaccines that bolster the natural immune system to combat cancer and infectious diseases. The company's approach centers on activating both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems. ImmunityBio's pipeline includes novel cell and immunotherapy agents designed to create durable immunological memory and long-lasting protection against diseases.

As of April 2025, ImmunityBio continues to advance its research and development efforts, with several ongoing clinical trials evaluating the efficacy and safety of its investigational therapies. The company's primary focus remains on its core platforms, including the Nant Cancer Vaccine, Anktiva™ (nogapendekin alfa inbakicept), and various infectious disease vaccines. These initiatives aim to address unmet medical needs in oncology and infectious diseases. The company's recent financial reports and investor updates provide further details on its progress and outlook.

In the fiscal year 2024, ImmunityBio reported significant financial activity, reflecting its ongoing clinical trials and research initiatives. While the company is still in a development stage and not yet generating substantial product revenue, strategic investments in research and development remain a priority. Key financial highlights from the 2024 reports include:

• Research and Development Expenses: A significant portion of the company's expenditure was allocated to advancing its clinical programs.
• Cash Position: ImmunityBio maintains a focus on managing its cash reserves to fund ongoing operations and future growth initiatives.
• Strategic Collaborations: The company continues to explore partnerships and collaborations to support the development and commercialization of its pipeline products.

While specific revenue figures for 2024 are not detailed, ImmunityBio's financial strategy revolves around securing funding through various means, including private placements and strategic collaborations, to support its extensive clinical development programs.

ImmunityBio stands out as a pioneering force in the immunotherapy landscape, driven by its innovative approach to harnessing the power of the immune system. Its commitment to developing groundbreaking therapies and vaccines positions it as a key player in the fight against cancer and infectious diseases. Interested in learning more about ImmunityBio? Discover more about the company and its potential impact on the future of medicine here: Exploring ImmunityBio, Inc. (IBRX) Investor Profile: Who’s Buying and Why?

ImmunityBio, Inc. (IBRX) Mission Statement

ImmunityBio, Inc. is dedicated to revolutionizing cancer treatment and enhancing patient outcomes through innovative immunotherapy solutions. The company strives to leverage and harmonize with the body's immune system to clear disease while ensuring its therapies also protect the immune system from damage.

The mission is to continuously pursue new therapies that kill disease, not the immune system. ImmunityBio's major focus is the development of novel treatments for advanced cancers and infectious diseases. They believe their science has the potential to change the current paradigm of care for these diseases.

ImmunityBio aims to make a meaningful difference in the lives of cancer patients and their families. The company never loses sight of who they serve: people with serious diseases who may be helped by the innovative therapies they conceive, design, and develop. It's those people who inspire their team of scientists, doctors, and staff every day.

The company measures its success by the quality of life they can offer to patients. ImmunityBio is on a mission to provide innovative therapies for patients with limited treatment options. The U.S. launch of ANKTIVA for NMIBC CIS has gained momentum, with the product now widely accessible through commercial and government insurance programs.

ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease.

A culture where patients come first, the people of ImmunityBio work tirelessly to transform their living biological technologies into innovative treatments that will improve the lives of people around the world.

Vision

ImmunityBio's vision is to create a world where cancer is no longer a life-threatening disease. This vision inspires progress and pushes boundaries to achieve a future where cancer is eradicated. Founder Dr. Patrick Soon-Shiong developed a vision that activation and proliferation of key lymphocytes was necessary if we were to win the war against cancer.

Dr. Soon-Shiong's 35-year quest is to change the paradigm of cancer care. This vision, which he has pursued for decades, is the transformation in the paradigm for cancer care by treating the host and activating the immune system (NK cell and killer T cell) resulting in immunogenic cell death and inducing long-term duration of response with the generation of memory T cells and memory NK cells.

Based on the vision of activating the patient's immune system, the company continues its efforts to demonstrate that a universal cancer vaccine that leverages the power of its platforms – backbone ANKTIVA, off-the-shelf and autologous NK-cell-based therapies, adenovirus-vectored delivered vaccines, and other technologies – provide benefit and hope not only for patients with cancer but also for those with a high risk of developing cancer.

With the merger complete, ImmunityBio has the scale that will allow it to advance its development of more novel therapies in oncology and infectious diseases, and accelerate work on its unique COVID-19 vaccine, which we believe is key to creating long-term immunity to the SARS-CoV-2 virus.

Core Values

At ImmunityBio, the core values are the foundation of everything they do. They believe in upholding these values in every aspect of their business to ensure that they are always working towards their mission of developing innovative immunotherapy treatments to combat cancer.

• Integrity: ImmunityBio is committed to conducting its business with the highest level of integrity. They believe in being honest, transparent, and ethical in all of their interactions.
• Innovation: ImmunityBio strives to push the boundaries of science and technology to develop groundbreaking treatments that have the potential to revolutionize cancer care.

Patient-Centricity influences every aspect of its operations, from research and development to clinical trials and commercialization. They prioritize the needs and well-being of patients in everything they do, ensuring that their efforts are always focused on delivering meaningful outcomes for those they aim to help.

Acting with integrity depends on each of us giving our full commitment. The responsibility lies with all of us. Conducting themselves with integrity helps them build confidence within and enhance collaboration among their teams. Importantly, conducting themselves with integrity helps them earn the trust and respect of the people they serve, the patients who benefit from their products.

The company's commitment to doing the right thing, which means complying with both the spirit and the letter of the laws that govern our industry, gives them a competitive advantage. Protecting ImmunityBio's intellectual property is essential to maintaining the Company's competitive advantage.

ImmunityBio, Inc. (IBRX) Vision Statement of

ImmunityBio, Inc. (IBRX), a clinical-stage immunotherapy company, is focused on developing therapies and vaccines that bolster the natural immune system to fight cancer and infectious diseases. Understanding the company's vision, mission, and core values provides insight into its strategic direction and operational priorities. As of April 2025, these guiding principles reflect ImmunityBio's commitment to innovation and patient care.

Mission Statement

ImmunityBio's mission is centered around developing cutting-edge immunotherapies to combat cancer and infectious diseases. This involves:

• Pioneering the development of next-generation therapies that harness the body's immune system.
• Conducting rigorous clinical trials to validate the safety and efficacy of their immunotherapeutic candidates.
• Collaborating with leading research institutions and healthcare providers to accelerate the development and delivery of novel treatments.
• Focusing on indications with high unmet medical needs, aiming to transform the standard of care for patients.

Vision Statement

The vision of ImmunityBio is to revolutionize the treatment of cancer and infectious diseases through innovative immunotherapies. This encompasses:

• Creating a broad portfolio of immunotherapeutic products that address a wide range of cancers and infectious diseases.
• Establishing a leadership position in the field of immunotherapy, recognized for scientific excellence and clinical innovation.
• Driving the adoption of their immunotherapies as first-line treatments, improving patient outcomes and quality of life.
• Expanding global access to their therapies, ensuring that patients around the world can benefit from their innovative treatments.

Core Values

ImmunityBio's core values are the fundamental beliefs that guide the company's actions and decisions. These include:

• Innovation: Commitment to pushing the boundaries of scientific knowledge and developing groundbreaking immunotherapies.
• Integrity: Adherence to the highest ethical standards in research, development, and commercialization.
• Collaboration: Fostering strong partnerships with researchers, clinicians, and patient advocacy groups.
• Patient-Centricity: Prioritizing the needs and well-being of patients in all aspects of their work.
• Excellence: Striving for the highest standards of quality and performance in all endeavors.

These core values drive ImmunityBio's commitment to make a meaningful difference in the lives of patients. For more in-depth information, you can explore Exploring ImmunityBio, Inc. (IBRX) Investor Profile: Who’s Buying and Why?.

ImmunityBio, Inc. (IBRX) Core Values of

While specific, publicly available details regarding ImmunityBio's mission statement, vision, and core values are limited, we can analyze the company's actions and statements to infer key principles that guide its operations.

Based on available information, the inferred core values revolve around innovation, patient-centricity, and a commitment to scientific advancement. These values are evident in ImmunityBio's focus on developing novel immunotherapies and its dedication to addressing unmet medical needs.

Here's an overview of the inferred core values of ImmunityBio, supported by examples and related data:

Innovation: Pioneering Next-Generation Immunotherapies

Innovation appears to be a central value for ImmunityBio. This is reflected in their focus on developing cutting-edge immunotherapies and cancer vaccines designed to harness the body's natural defenses to fight disease. As of the fiscal year 2024, ImmunityBio's R&D expenditure was approximately $350 million, highlighting their commitment to innovation. The company’s pipeline includes several novel therapies, such as:

• Anktiva (nogapendekin alfa inbakicept-pmln): A novel interleukin-15 (IL-15) superagonist, is designed to activate the body's NK cells and T cells to fight cancer.
• PD-L1 t-haNK: Genetically engineered human natural killer cells targeting PD-L1 expressing tumors.

The company has also collaborated with academic institutions and other biotech firms to advance its research efforts. For instance, ImmunityBio is working with clinical research institutions to explore new treatment combinations and indications for its therapies. The company’s innovative approach is further underscored by its intellectual property portfolio, which includes numerous patents and patent applications covering its core technologies.

Patient-Centricity: Addressing Unmet Medical Needs

ImmunityBio emphasizes a patient-centric approach, focusing on developing therapies that address critical unmet medical needs in cancer and infectious diseases. This commitment is evident in the company's clinical trial designs, which often prioritize patient quality of life and overall survival. For example, ImmunityBio's trials for bladder cancer and pancreatic cancer have shown promising results, with some patients experiencing durable responses and improved survival rates. In 2024, the company reported that 40% of patients with non-muscle invasive bladder cancer (NMIBC) treated with Anktiva achieved complete remission. The company supports patient advocacy groups and participates in awareness campaigns to educate patients and healthcare providers about new treatment options. By prioritizing patient needs and outcomes, ImmunityBio aims to make a meaningful difference in the lives of those affected by serious illnesses.

Scientific Advancement: Commitment to Research and Development

ImmunityBio places a high value on scientific advancement, continually investing in research and development to improve its understanding of the immune system and develop more effective therapies. This commitment is reflected in the company's extensive preclinical and clinical research programs, which involve collaborations with leading scientists and medical institutions. The company’s research efforts are focused on:

• Understanding the mechanisms of action of its immunotherapies.
• Identifying biomarkers that can predict patient response to treatment.
• Developing new combination therapies that can overcome resistance to existing treatments.

In 2024, ImmunityBio presented data from several clinical trials at major scientific conferences, showcasing the potential of its therapies to improve patient outcomes. The company also publishes its research findings in peer-reviewed journals, contributing to the broader scientific community. The company’s dedication to scientific rigor and innovation drives its efforts to develop transformative therapies for patients with cancer and infectious diseases.

ImmunityBio’s dedication to these inferred core values underscores its position as a pioneering force in the biotechnology industry, striving to transform the treatment landscape for cancer and infectious diseases.